A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer

Prior treatment

• Participants who have a contraindication to MRI identified by the MR procedure screening form, such as a pacemaker, aneurysm clip, inner ear implant, neurostimulator, or other non-MR-compatible device or implant

Other illness

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• Participants must have a biopsy-proven diagnosis of cervical cancer for which interstitial brachytherapy is planned as standard treatment
• Age 18 years or older
• ECOG performance status of 2 or less (see Appendix A)
• Patients who have received prior radiation or chemotherapy may be enrolled on this study
• Participant is deemed to be an appropriate candidate for MR-guided brachytherapy by the radiation oncologist and the patient elects to be treated with MR-guided brachytherapy
• Participant provides informed consent for prospective collection of relevant medical records for analysis of clinical outcome and treatment-planning techniques
• Ability to understand and the willingness to sign a written informed consent document. Participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow- up